TY - CHAP
T1 - Comprehensive analysis of MHC ligands in clinical material by immunoaffinity-mass spectrometry
AU - Kasuga, Kie
PY - 2013
Y1 - 2013
N2 - Major histocompatibility complexes (MHC) are expressed on antigen-presenting cells (APC) that display peptide antigens. This is a crucial step to activate a T-cell response. Since immunogenic ligand of MHC is closely related with autoimmunity, inflammatory diseases, and cancer, comprehensive analysis of MHC ligands (the so-called Ligandome) is essential to unveil disease pathogenesis. Recently, immunotherapies such as vaccination have been focused on as new therapies of cancer, HIV, and infectious diseases. Therefore, the importance of comprehensive analysis of MHC ligands is increasing. Mass spectrometry has been the core technology of ligand identification since the 1990s. The sensitivity of mass spectrometers has been improved dramatically in recent years; thus, it enables to identify MHC ligands in clinical materials. This chapter lays out the workflow of MHC ligand identification in clinical materials, especially human bronchoalveolar (BAL) cells. MHC-ligand complexes are enriched by immunoaffinity extraction and captured ligand peptides are identified by LC-MS/MS. MHC class II ligand in BAL cells is described in this text; however, this approach is applicable to MHC class I and other clinical materials such as tissues.
AB - Major histocompatibility complexes (MHC) are expressed on antigen-presenting cells (APC) that display peptide antigens. This is a crucial step to activate a T-cell response. Since immunogenic ligand of MHC is closely related with autoimmunity, inflammatory diseases, and cancer, comprehensive analysis of MHC ligands (the so-called Ligandome) is essential to unveil disease pathogenesis. Recently, immunotherapies such as vaccination have been focused on as new therapies of cancer, HIV, and infectious diseases. Therefore, the importance of comprehensive analysis of MHC ligands is increasing. Mass spectrometry has been the core technology of ligand identification since the 1990s. The sensitivity of mass spectrometers has been improved dramatically in recent years; thus, it enables to identify MHC ligands in clinical materials. This chapter lays out the workflow of MHC ligand identification in clinical materials, especially human bronchoalveolar (BAL) cells. MHC-ligand complexes are enriched by immunoaffinity extraction and captured ligand peptides are identified by LC-MS/MS. MHC class II ligand in BAL cells is described in this text; however, this approach is applicable to MHC class I and other clinical materials such as tissues.
KW - Bronchoalveolar lavage (BAL)
KW - Comprehensive analysis
KW - Immunoaffinity extraction
KW - Ligand
KW - Major histocompatibility complexes (MHC)
UR - http://www.scopus.com/inward/record.url?scp=84880756368&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84880756368&partnerID=8YFLogxK
U2 - 10.1007/978-1-4614-7209-4_14
DO - 10.1007/978-1-4614-7209-4_14
M3 - Chapter
C2 - 23765629
AN - SCOPUS:84880756368
SN - 9781461471677
T3 - Methods in Molecular Biology
SP - 203
EP - 218
BT - The Low Molecular Weight Proteome
PB - Humana Press Inc.
ER -
